Yuet-Kin Leung
Concepts (458)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Estrogen Receptor beta | 17 | 2019 | 54 | 3.310 |
Why?
| | Endocrine Disruptors | 7 | 2025 | 34 | 2.590 |
Why?
| | Prostatic Neoplasms | 15 | 2022 | 398 | 2.500 |
Why?
| | Epigenesis, Genetic | 11 | 2025 | 396 | 1.960 |
Why?
| | Phenols | 10 | 2025 | 96 | 1.960 |
Why?
| | Benzhydryl Compounds | 9 | 2021 | 70 | 1.910 |
Why?
| | Environmental Pollutants | 4 | 2024 | 104 | 1.520 |
Why?
| | DNA Methylation | 13 | 2025 | 573 | 1.310 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2024 | 853 | 1.180 |
Why?
| | Estrogens | 7 | 2020 | 228 | 1.170 |
Why?
| | Cell Line, Tumor | 21 | 2024 | 1429 | 0.990 |
Why?
| | Signal Transduction | 12 | 2021 | 1724 | 0.930 |
Why?
| | Estradiol | 9 | 2021 | 226 | 0.920 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2024 | 208 | 0.870 |
Why?
| | Breast Neoplasms | 7 | 2016 | 1203 | 0.850 |
Why?
| | beta Catenin | 1 | 2024 | 105 | 0.820 |
Why?
| | Cell Movement | 4 | 2020 | 271 | 0.820 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 96 | 0.810 |
Why?
| | Endocrine System | 1 | 2023 | 16 | 0.810 |
Why?
| | Receptors, Androgen | 2 | 2022 | 48 | 0.790 |
Why?
| | Liver Neoplasms | 2 | 2024 | 341 | 0.760 |
Why?
| | Occupational Exposure | 3 | 2021 | 111 | 0.740 |
Why?
| | Mice, Knockout | 2 | 2024 | 903 | 0.740 |
Why?
| | Antineoplastic Agents | 5 | 2021 | 1216 | 0.730 |
Why?
| | Cell Proliferation | 10 | 2022 | 1013 | 0.730 |
Why?
| | Environmental Exposure | 7 | 2024 | 225 | 0.680 |
Why?
| | Protein Kinase Inhibitors | 5 | 2023 | 231 | 0.670 |
Why?
| | Toxicity Tests | 1 | 2020 | 57 | 0.670 |
Why?
| | Humans | 64 | 2025 | 52441 | 0.630 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2017 | 122 | 0.610 |
Why?
| | Animals | 26 | 2024 | 13485 | 0.590 |
Why?
| | Chromosomes, Human, X | 1 | 2018 | 18 | 0.570 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2023 | 202 | 0.510 |
Why?
| | Protective Clothing | 1 | 2015 | 6 | 0.480 |
Why?
| | Firefighters | 1 | 2015 | 3 | 0.480 |
Why?
| | Estrogen Antagonists | 1 | 2015 | 21 | 0.480 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2014 | 56 | 0.470 |
Why?
| | Transcriptional Activation | 4 | 2013 | 127 | 0.450 |
Why?
| | Response Elements | 2 | 2013 | 29 | 0.450 |
Why?
| | MicroRNAs | 3 | 2016 | 392 | 0.430 |
Why?
| | CpG Islands | 8 | 2025 | 111 | 0.420 |
Why?
| | Female | 34 | 2025 | 28277 | 0.420 |
Why?
| | Prostate | 6 | 2016 | 116 | 0.420 |
Why?
| | Fetal Blood | 3 | 2025 | 78 | 0.420 |
Why?
| | Promoter Regions, Genetic | 4 | 2019 | 465 | 0.410 |
Why?
| | Sp1 Transcription Factor | 2 | 2024 | 20 | 0.400 |
Why?
| | Prenatal Exposure Delayed Effects | 4 | 2021 | 196 | 0.400 |
Why?
| | Exons | 1 | 2013 | 101 | 0.400 |
Why?
| | Apoptosis | 4 | 2022 | 1120 | 0.390 |
Why?
| | Male | 34 | 2024 | 26874 | 0.390 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 125 | 0.390 |
Why?
| | Rats | 11 | 2021 | 3228 | 0.390 |
Why?
| | Diet, High-Fat | 4 | 2021 | 230 | 0.360 |
Why?
| | Maternal Exposure | 3 | 2025 | 96 | 0.340 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2022 | 33 | 0.340 |
Why?
| | Muscle Proteins | 1 | 2013 | 343 | 0.340 |
Why?
| | Placenta | 2 | 2025 | 147 | 0.330 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2019 | 224 | 0.330 |
Why?
| | Receptors, Estrogen | 4 | 2019 | 133 | 0.320 |
Why?
| | Pregnancy | 11 | 2025 | 2642 | 0.320 |
Why?
| | Adenocarcinoma | 2 | 2011 | 403 | 0.320 |
Why?
| | Pyrimidines | 2 | 2022 | 199 | 0.320 |
Why?
| | Spermatogenesis | 2 | 2021 | 16 | 0.310 |
Why?
| | RNA, Messenger | 5 | 2022 | 1134 | 0.300 |
Why?
| | HEK293 Cells | 5 | 2021 | 236 | 0.290 |
Why?
| | Air Pollutants, Occupational | 2 | 2020 | 14 | 0.290 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2021 | 1365 | 0.290 |
Why?
| | Orphan Nuclear Receptors | 2 | 2019 | 14 | 0.290 |
Why?
| | fms-Like Tyrosine Kinase 3 | 3 | 2023 | 20 | 0.280 |
Why?
| | Transcription, Genetic | 4 | 2013 | 375 | 0.280 |
Why?
| | Mass Spectrometry | 2 | 2024 | 294 | 0.270 |
Why?
| | Epigenomics | 2 | 2019 | 75 | 0.270 |
Why?
| | Mutation | 5 | 2023 | 1331 | 0.260 |
Why?
| | Protein Isoforms | 4 | 2013 | 127 | 0.260 |
Why?
| | Metabolome | 2 | 2025 | 100 | 0.260 |
Why?
| | Mice | 6 | 2024 | 5899 | 0.260 |
Why?
| | Gene Expression Profiling | 5 | 2015 | 1099 | 0.250 |
Why?
| | Phosphorylation | 5 | 2021 | 536 | 0.250 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2005 | 26 | 0.230 |
Why?
| | Androgens | 2 | 2022 | 70 | 0.230 |
Why?
| | Lung Neoplasms | 3 | 2022 | 643 | 0.230 |
Why?
| | Protein Processing, Post-Translational | 3 | 2012 | 152 | 0.230 |
Why?
| | Veterans | 2 | 2021 | 573 | 0.220 |
Why?
| | Chironomidae | 1 | 2004 | 1 | 0.220 |
Why?
| | Ferrochelatase | 1 | 2004 | 1 | 0.220 |
Why?
| | Aqueous Humor | 1 | 2024 | 10 | 0.220 |
Why?
| | Retinal Artery Occlusion | 1 | 2024 | 11 | 0.220 |
Why?
| | NF-kappa B | 1 | 2006 | 326 | 0.220 |
Why?
| | Structure-Activity Relationship | 5 | 2022 | 399 | 0.220 |
Why?
| | Nanoparticles | 2 | 2016 | 131 | 0.220 |
Why?
| | Butter | 2 | 2021 | 4 | 0.210 |
Why?
| | Copper | 1 | 2004 | 47 | 0.210 |
Why?
| | Proteome | 1 | 2006 | 175 | 0.210 |
Why?
| | Glycyrrhiza | 1 | 2003 | 3 | 0.210 |
Why?
| | Pyridines | 2 | 2023 | 137 | 0.210 |
Why?
| | Drug Discovery | 2 | 2021 | 94 | 0.210 |
Why?
| | Wounds and Injuries | 2 | 2018 | 300 | 0.210 |
Why?
| | Disease Models, Animal | 3 | 2024 | 1483 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2003 | 61 | 0.210 |
Why?
| | Proteins | 2 | 2006 | 353 | 0.210 |
Why?
| | Binding Sites | 2 | 2022 | 379 | 0.200 |
Why?
| | Hormones | 1 | 2023 | 57 | 0.200 |
Why?
| | Antineoplastic Agents, Phytogenic | 3 | 2016 | 71 | 0.190 |
Why?
| | Tumor Suppressor Proteins | 2 | 2020 | 127 | 0.190 |
Why?
| | Neoplasm Invasiveness | 2 | 2014 | 278 | 0.190 |
Why?
| | Methylcholanthrene | 1 | 2002 | 10 | 0.190 |
Why?
| | Sp3 Transcription Factor | 1 | 2022 | 5 | 0.190 |
Why?
| | RNA Polymerase II | 1 | 2022 | 14 | 0.180 |
Why?
| | Infertility, Male | 1 | 2021 | 11 | 0.180 |
Why?
| | Proteomics | 1 | 2024 | 332 | 0.180 |
Why?
| | Aminoquinolines | 1 | 2021 | 8 | 0.180 |
Why?
| | Phthalazines | 1 | 2021 | 20 | 0.180 |
Why?
| | Thiophenes | 1 | 2021 | 45 | 0.180 |
Why?
| | Disease Susceptibility | 2 | 2012 | 97 | 0.170 |
Why?
| | Computational Biology | 3 | 2019 | 209 | 0.170 |
Why?
| | Forkhead Transcription Factors | 2 | 2012 | 120 | 0.170 |
Why?
| | Plant Extracts | 1 | 2003 | 199 | 0.170 |
Why?
| | Glucuronosyltransferase | 1 | 2002 | 121 | 0.170 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 455 | 0.170 |
Why?
| | Risk | 3 | 2017 | 315 | 0.170 |
Why?
| | Dietary Fats | 1 | 2021 | 134 | 0.170 |
Why?
| | Adult | 11 | 2025 | 14205 | 0.170 |
Why?
| | Infant, Newborn | 4 | 2025 | 2871 | 0.170 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 141 | 0.170 |
Why?
| | Transforming Growth Factor beta | 1 | 2021 | 136 | 0.170 |
Why?
| | DNA Modification Methylases | 1 | 2020 | 28 | 0.160 |
Why?
| | Estrogen Receptor alpha | 3 | 2019 | 86 | 0.160 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2020 | 21 | 0.160 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2020 | 44 | 0.160 |
Why?
| | DNA Repair Enzymes | 1 | 2020 | 42 | 0.160 |
Why?
| | Molecular Sequence Data | 4 | 2006 | 778 | 0.160 |
Why?
| | Pyruvate Kinase | 1 | 2020 | 7 | 0.160 |
Why?
| | Pyrroles | 1 | 2020 | 73 | 0.160 |
Why?
| | Hair | 2 | 2018 | 29 | 0.160 |
Why?
| | Drug Design | 1 | 2020 | 122 | 0.160 |
Why?
| | Up-Regulation | 3 | 2019 | 462 | 0.160 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 96 | 0.160 |
Why?
| | Random Allocation | 2 | 2017 | 286 | 0.160 |
Why?
| | Pharyngeal Neoplasms | 1 | 2019 | 1 | 0.160 |
Why?
| | Endometrial Neoplasms | 1 | 2020 | 144 | 0.150 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 22 | 0.150 |
Why?
| | Glioma | 1 | 2020 | 83 | 0.150 |
Why?
| | Collagen Type III | 1 | 2019 | 7 | 0.150 |
Why?
| | Subcellular Fractions | 2 | 2012 | 33 | 0.150 |
Why?
| | Cost of Illness | 2 | 2018 | 120 | 0.150 |
Why?
| | Amino Acid Sequence | 3 | 2006 | 576 | 0.150 |
Why?
| | Liver Failure, Acute | 1 | 2019 | 56 | 0.150 |
Why?
| | Tissue Array Analysis | 3 | 2016 | 45 | 0.140 |
Why?
| | Military Personnel | 1 | 2020 | 175 | 0.140 |
Why?
| | Stress, Psychological | 1 | 2020 | 275 | 0.140 |
Why?
| | Methylmercury Compounds | 1 | 2018 | 4 | 0.140 |
Why?
| | Collagen Type I | 1 | 2019 | 83 | 0.140 |
Why?
| | Mortality, Premature | 1 | 2018 | 12 | 0.140 |
Why?
| | Denmark | 1 | 2018 | 55 | 0.140 |
Why?
| | Depressive Disorder | 1 | 2020 | 335 | 0.140 |
Why?
| | Polychlorinated Biphenyls | 1 | 2018 | 36 | 0.140 |
Why?
| | Anxiety | 1 | 2020 | 305 | 0.140 |
Why?
| | Pregnancy in Diabetics | 1 | 2018 | 25 | 0.140 |
Why?
| | Water Pollutants, Chemical | 1 | 2018 | 54 | 0.140 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2017 | 30 | 0.140 |
Why?
| | Histone Demethylases | 1 | 2017 | 18 | 0.140 |
Why?
| | Urethane | 1 | 2017 | 5 | 0.140 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 175 | 0.130 |
Why?
| | Neoplasms | 2 | 2005 | 1314 | 0.130 |
Why?
| | Morbidity | 1 | 2018 | 137 | 0.130 |
Why?
| | Cells, Cultured | 4 | 2019 | 1583 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.130 |
Why?
| | Protein Binding | 2 | 2011 | 673 | 0.130 |
Why?
| | Mammary Glands, Animal | 1 | 2017 | 68 | 0.130 |
Why?
| | Gene Expression | 2 | 2018 | 618 | 0.130 |
Why?
| | Rats, Sprague-Dawley | 5 | 2021 | 1558 | 0.130 |
Why?
| | Immunohistochemistry | 4 | 2016 | 977 | 0.130 |
Why?
| | Fibroblasts | 1 | 2019 | 357 | 0.130 |
Why?
| | Research Design | 1 | 2019 | 368 | 0.130 |
Why?
| | Cholesterol | 1 | 2017 | 159 | 0.130 |
Why?
| | 5-Methylcytosine | 1 | 2016 | 16 | 0.130 |
Why?
| | Brain Neoplasms | 1 | 2020 | 302 | 0.130 |
Why?
| | Sex Characteristics | 1 | 2018 | 210 | 0.120 |
Why?
| | Heart Diseases | 1 | 2019 | 217 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2019 | 331 | 0.120 |
Why?
| | Environmental Health | 1 | 2016 | 14 | 0.120 |
Why?
| | Paclitaxel | 1 | 2016 | 91 | 0.120 |
Why?
| | Membrane Proteins | 2 | 2010 | 344 | 0.120 |
Why?
| | Developed Countries | 1 | 2016 | 17 | 0.120 |
Why?
| | Sexual Maturation | 1 | 2015 | 19 | 0.120 |
Why?
| | Reproduction | 1 | 2016 | 66 | 0.120 |
Why?
| | Pandemics | 1 | 2020 | 580 | 0.120 |
Why?
| | Risk Factors | 5 | 2020 | 3971 | 0.120 |
Why?
| | Embryo Implantation | 1 | 2015 | 5 | 0.120 |
Why?
| | Myocardium | 1 | 2019 | 471 | 0.120 |
Why?
| | Embryonic Development | 1 | 2015 | 19 | 0.120 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 96 | 0.120 |
Why?
| | Developing Countries | 1 | 2016 | 64 | 0.120 |
Why?
| | Interferons | 1 | 2015 | 38 | 0.120 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2016 | 57 | 0.120 |
Why?
| | RNA, Untranslated | 1 | 2015 | 15 | 0.120 |
Why?
| | Prostatectomy | 1 | 2016 | 84 | 0.120 |
Why?
| | Histone Code | 1 | 2015 | 32 | 0.120 |
Why?
| | Polyglycolic Acid | 1 | 2015 | 7 | 0.120 |
Why?
| | Myeloid Cells | 1 | 2015 | 42 | 0.120 |
Why?
| | Histidine | 1 | 2015 | 16 | 0.120 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2015 | 35 | 0.110 |
Why?
| | Tumor Cells, Cultured | 3 | 2022 | 441 | 0.110 |
Why?
| | Particle Size | 1 | 2015 | 76 | 0.110 |
Why?
| | Middle Aged | 8 | 2024 | 13133 | 0.110 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2016 | 234 | 0.110 |
Why?
| | Aged | 7 | 2024 | 10242 | 0.110 |
Why?
| | Drug Carriers | 1 | 2015 | 68 | 0.110 |
Why?
| | Receptor, erbB-2 | 1 | 2015 | 79 | 0.110 |
Why?
| | Lysosomes | 1 | 2015 | 65 | 0.110 |
Why?
| | Inflammasomes | 1 | 2015 | 64 | 0.110 |
Why?
| | Polyethylene Glycols | 1 | 2015 | 93 | 0.110 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2014 | 47 | 0.110 |
Why?
| | HMGA Proteins | 1 | 2014 | 2 | 0.110 |
Why?
| | Lactic Acid | 1 | 2015 | 79 | 0.110 |
Why?
| | Base Sequence | 3 | 2005 | 632 | 0.110 |
Why?
| | Maternal Mortality | 1 | 2014 | 29 | 0.110 |
Why?
| | Malaria | 1 | 2014 | 35 | 0.110 |
Why?
| | Isoenzymes | 2 | 2005 | 171 | 0.110 |
Why?
| | Caspase 7 | 1 | 2013 | 7 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 485 | 0.100 |
Why?
| | Histones | 2 | 2015 | 315 | 0.100 |
Why?
| | MCF-7 Cells | 1 | 2013 | 63 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2014 | 150 | 0.100 |
Why?
| | Tuberculosis | 1 | 2014 | 127 | 0.100 |
Why?
| | 5' Untranslated Regions | 1 | 2013 | 30 | 0.100 |
Why?
| | Histone Acetyltransferases | 1 | 2013 | 25 | 0.100 |
Why?
| | Open Reading Frames | 1 | 2013 | 54 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 148 | 0.100 |
Why?
| | HIV Infections | 2 | 2014 | 394 | 0.100 |
Why?
| | DNA | 1 | 2016 | 544 | 0.100 |
Why?
| | Vehicle Emissions | 1 | 2012 | 10 | 0.100 |
Why?
| | Estrogens, Non-Steroidal | 2 | 2015 | 16 | 0.100 |
Why?
| | Metabolomics | 2 | 2025 | 147 | 0.100 |
Why?
| | Models, Biological | 2 | 2017 | 735 | 0.100 |
Why?
| | Transcriptome | 1 | 2015 | 357 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 525 | 0.100 |
Why?
| | Air Pollutants | 1 | 2012 | 78 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 504 | 0.090 |
Why?
| | RNA Splicing | 1 | 2012 | 43 | 0.090 |
Why?
| | Doxorubicin | 1 | 2013 | 246 | 0.090 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 83 | 0.090 |
Why?
| | Cisplatin | 1 | 2013 | 282 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 94 | 0.090 |
Why?
| | Antibodies | 1 | 2012 | 144 | 0.090 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 128 | 0.090 |
Why?
| | Diet | 1 | 2015 | 591 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 580 | 0.090 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2011 | 37 | 0.090 |
Why?
| | Protein Biosynthesis | 1 | 2013 | 267 | 0.090 |
Why?
| | Racemases and Epimerases | 1 | 2011 | 18 | 0.090 |
Why?
| | Cell Cycle | 1 | 2012 | 236 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2017 | 187 | 0.080 |
Why?
| | Models, Genetic | 1 | 2011 | 173 | 0.080 |
Why?
| | Molecular Structure | 2 | 2021 | 317 | 0.080 |
Why?
| | Cell Nucleus | 2 | 2016 | 189 | 0.080 |
Why?
| | Introns | 1 | 2010 | 53 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2015 | 1004 | 0.080 |
Why?
| | Carcinogens | 2 | 2015 | 194 | 0.080 |
Why?
| | Testosterone | 2 | 2016 | 145 | 0.080 |
Why?
| | Gene Silencing | 1 | 2010 | 122 | 0.080 |
Why?
| | Manganese Poisoning | 1 | 2009 | 5 | 0.080 |
Why?
| | Young Adult | 4 | 2025 | 4346 | 0.080 |
Why?
| | Disease-Free Survival | 1 | 2010 | 461 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 446 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2007 | 412 | 0.070 |
Why?
| | Asthma | 1 | 2012 | 313 | 0.070 |
Why?
| | Methylation | 2 | 2020 | 124 | 0.070 |
Why?
| | Enzyme Activation | 2 | 2006 | 269 | 0.070 |
Why?
| | Community-Based Participatory Research | 1 | 2009 | 202 | 0.070 |
Why?
| | Sequence Analysis, DNA | 2 | 2019 | 220 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 2 | 2018 | 67 | 0.060 |
Why?
| | Apigenin | 1 | 2006 | 7 | 0.060 |
Why?
| | Estrogen Receptor Modulators | 1 | 2006 | 5 | 0.060 |
Why?
| | Presenilin-2 | 1 | 2006 | 3 | 0.060 |
Why?
| | Yeasts | 1 | 2006 | 9 | 0.060 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 19 | 0.060 |
Why?
| | Dimerization | 1 | 2006 | 51 | 0.060 |
Why?
| | Growth Differentiation Factor 1 | 1 | 2006 | 2 | 0.060 |
Why?
| | Interleukin-12 | 1 | 2006 | 26 | 0.060 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2006 | 51 | 0.060 |
Why?
| | Sex Factors | 2 | 2019 | 735 | 0.060 |
Why?
| | Interleukin-8 | 1 | 2006 | 86 | 0.060 |
Why?
| | Mortality | 2 | 2018 | 100 | 0.060 |
Why?
| | Cohort Studies | 1 | 2010 | 1576 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2006 | 106 | 0.060 |
Why?
| | Benzo(a)pyrene | 1 | 2005 | 13 | 0.060 |
Why?
| | Epithelium | 1 | 2005 | 65 | 0.060 |
Why?
| | Models, Molecular | 1 | 2006 | 356 | 0.060 |
Why?
| | Phthalic Acids | 1 | 2025 | 7 | 0.060 |
Why?
| | Molecular Conformation | 1 | 2005 | 67 | 0.060 |
Why?
| | Genes, p53 | 1 | 2005 | 50 | 0.060 |
Why?
| | Genes, Tumor Suppressor | 1 | 2005 | 73 | 0.060 |
Why?
| | Ovary | 1 | 2005 | 101 | 0.060 |
Why?
| | Alternative Splicing | 1 | 2005 | 61 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2025 | 122 | 0.060 |
Why?
| | Cations, Divalent | 1 | 2004 | 6 | 0.060 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2024 | 10 | 0.060 |
Why?
| | Vitreous Body | 1 | 2024 | 18 | 0.060 |
Why?
| | Iron-Sulfur Proteins | 1 | 2004 | 9 | 0.050 |
Why?
| | Paracentesis | 1 | 2024 | 13 | 0.050 |
Why?
| | Eye Proteins | 1 | 2024 | 16 | 0.050 |
Why?
| | Transfection | 1 | 2005 | 365 | 0.050 |
Why?
| | Organizational Objectives | 2 | 2014 | 35 | 0.050 |
Why?
| | Survival Analysis | 2 | 2016 | 656 | 0.050 |
Why?
| | Metals | 1 | 2004 | 37 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2004 | 121 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2004 | 181 | 0.050 |
Why?
| | Age Distribution | 2 | 2014 | 176 | 0.050 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 1 | 2003 | 2 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2003 | 7 | 0.050 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2003 | 11 | 0.050 |
Why?
| | Cell Survival | 2 | 2021 | 598 | 0.050 |
Why?
| | Glutathione S-Transferase pi | 1 | 2003 | 25 | 0.050 |
Why?
| | Deoxyguanosine | 1 | 2003 | 27 | 0.050 |
Why?
| | Blotting, Northern | 1 | 2003 | 107 | 0.050 |
Why?
| | Clone Cells | 1 | 2003 | 76 | 0.050 |
Why?
| | Vitrectomy | 1 | 2024 | 61 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2003 | 62 | 0.050 |
Why?
| | Pilot Projects | 2 | 2020 | 725 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2023 | 93 | 0.050 |
Why?
| | Glutathione Transferase | 1 | 2003 | 174 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 111 | 0.050 |
Why?
| | Kinetics | 1 | 2004 | 613 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 1888 | 0.050 |
Why?
| | Herbal Medicine | 1 | 2002 | 3 | 0.050 |
Why?
| | Dactinomycin | 1 | 2002 | 22 | 0.050 |
Why?
| | Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 15 | 0.050 |
Why?
| | RNA Stability | 1 | 2002 | 29 | 0.050 |
Why?
| | Inheritance Patterns | 1 | 2021 | 22 | 0.040 |
Why?
| | Smad Proteins | 1 | 2021 | 16 | 0.040 |
Why?
| | Incineration | 1 | 2021 | 5 | 0.040 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2021 | 29 | 0.040 |
Why?
| | Mitochondria | 1 | 2005 | 420 | 0.040 |
Why?
| | Prognosis | 2 | 2017 | 2100 | 0.040 |
Why?
| | Amino Acids | 1 | 2023 | 386 | 0.040 |
Why?
| | Testis | 1 | 2021 | 74 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 135 | 0.040 |
Why?
| | Staining and Labeling | 2 | 2016 | 92 | 0.040 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2021 | 58 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 141 | 0.040 |
Why?
| | Phytoestrogens | 2 | 2014 | 23 | 0.040 |
Why?
| | Small Molecule Libraries | 1 | 2021 | 66 | 0.040 |
Why?
| | Loneliness | 1 | 2020 | 15 | 0.040 |
Why?
| | Hypesthesia | 1 | 2020 | 16 | 0.040 |
Why?
| | Chemistry Techniques, Synthetic | 1 | 2020 | 21 | 0.040 |
Why?
| | Alcohol Oxidoreductases | 1 | 2020 | 13 | 0.040 |
Why?
| | Memory Disorders | 1 | 2020 | 52 | 0.040 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2020 | 4 | 0.040 |
Why?
| | Wound Healing | 1 | 2022 | 223 | 0.040 |
Why?
| | Child, Preschool | 3 | 2016 | 4046 | 0.040 |
Why?
| | Fear | 1 | 2020 | 84 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2019 | 38 | 0.040 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 227 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2003 | 805 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2019 | 101 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2019 | 223 | 0.040 |
Why?
| | Adolescent | 3 | 2016 | 6713 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 1677 | 0.040 |
Why?
| | Linear Models | 1 | 2019 | 288 | 0.040 |
Why?
| | Biopsy | 1 | 2020 | 594 | 0.040 |
Why?
| | Fibrosis | 1 | 2019 | 198 | 0.040 |
Why?
| | Aging | 1 | 2003 | 722 | 0.030 |
Why?
| | Diet, Atherogenic | 1 | 2017 | 10 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 38 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 2017 | 55 | 0.030 |
Why?
| | Calcium Phosphates | 1 | 2016 | 5 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 112 | 0.030 |
Why?
| | Lung | 1 | 2020 | 479 | 0.030 |
Why?
| | Acetaminophen | 1 | 2019 | 272 | 0.030 |
Why?
| | Genetic Loci | 1 | 2016 | 46 | 0.030 |
Why?
| | Child | 3 | 2016 | 7194 | 0.030 |
Why?
| | Polymers | 1 | 2016 | 51 | 0.030 |
Why?
| | Exercise | 1 | 2020 | 559 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 18 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 178 | 0.030 |
Why?
| | Age Factors | 2 | 2014 | 1120 | 0.030 |
Why?
| | Child Mortality | 1 | 2016 | 12 | 0.030 |
Why?
| | Ethinyl Estradiol | 1 | 2015 | 8 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2016 | 122 | 0.030 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2015 | 50 | 0.030 |
Why?
| | Environment | 1 | 2016 | 88 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2016 | 181 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2018 | 218 | 0.030 |
Why?
| | Sp Transcription Factors | 1 | 2014 | 6 | 0.030 |
Why?
| | Pentacyclic Triterpenes | 1 | 2014 | 8 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2015 | 236 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2015 | 65 | 0.030 |
Why?
| | Triterpenes | 1 | 2014 | 11 | 0.030 |
Why?
| | Lysine | 1 | 2015 | 90 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 86 | 0.030 |
Why?
| | Schools | 1 | 2016 | 175 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 78 | 0.030 |
Why?
| | Gestational Age | 1 | 2016 | 415 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2018 | 1202 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2015 | 109 | 0.030 |
Why?
| | Mice, Nude | 1 | 2014 | 230 | 0.030 |
Why?
| | Epidemics | 1 | 2014 | 26 | 0.030 |
Why?
| | Sex Distribution | 1 | 2014 | 138 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 182 | 0.030 |
Why?
| | Stem Cells | 1 | 2015 | 186 | 0.030 |
Why?
| | Genome | 1 | 2014 | 61 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2015 | 217 | 0.030 |
Why?
| | Blotting, Western | 1 | 2014 | 587 | 0.030 |
Why?
| | Acetylation | 1 | 2013 | 96 | 0.030 |
Why?
| | Cause of Death | 1 | 2014 | 157 | 0.030 |
Why?
| | Life Style | 1 | 2014 | 148 | 0.020 |
Why?
| | Models, Statistical | 1 | 2014 | 230 | 0.020 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2014 | 81 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 1223 | 0.020 |
Why?
| | Infant | 2 | 2012 | 3709 | 0.020 |
Why?
| | Saliva | 1 | 2012 | 56 | 0.020 |
Why?
| | Cell Line | 1 | 2015 | 1020 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 1016 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 639 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 609 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2013 | 201 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 570 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2013 | 312 | 0.020 |
Why?
| | Incidence | 1 | 2014 | 1096 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2010 | 69 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2010 | 71 | 0.020 |
Why?
| | Hemochromatosis | 1 | 2009 | 3 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2009 | 37 | 0.020 |
Why?
| | Ohio | 1 | 2009 | 46 | 0.020 |
Why?
| | Manganese | 1 | 2009 | 22 | 0.020 |
Why?
| | Obesity | 1 | 2018 | 1176 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2009 | 89 | 0.020 |
Why?
| | Dihydrotestosterone | 1 | 2007 | 14 | 0.020 |
Why?
| | Time Factors | 1 | 2014 | 2987 | 0.020 |
Why?
| | United States | 1 | 2018 | 5215 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 506 | 0.020 |
Why?
| | Anticarcinogenic Agents | 1 | 2006 | 32 | 0.020 |
Why?
| | Caspase 3 | 1 | 2006 | 91 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 348 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2006 | 217 | 0.020 |
Why?
| | TATA Box | 1 | 2004 | 8 | 0.010 |
Why?
| | Dinucleoside Phosphates | 1 | 2004 | 7 | 0.010 |
Why?
| | DNA Primers | 1 | 2004 | 204 | 0.010 |
Why?
| | Orchiectomy | 1 | 2003 | 38 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 2003 | 184 | 0.010 |
Why?
| | Oxidoreductases | 1 | 2003 | 56 | 0.010 |
Why?
| | Precancerous Conditions | 1 | 2004 | 87 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 6694 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2004 | 235 | 0.010 |
Why?
| | Aldehydes | 1 | 2003 | 81 | 0.010 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2003 | 2 | 0.010 |
Why?
| | Clusterin | 1 | 2003 | 8 | 0.010 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2003 | 6 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 169 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2003 | 38 | 0.010 |
Why?
| | Regeneration | 1 | 2003 | 79 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2003 | 92 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 2003 | 76 | 0.010 |
Why?
| | Glycoproteins | 1 | 2003 | 123 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2009 | 3449 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 239 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 768 | 0.010 |
Why?
|
|
Leung's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|